On 15 June 2026, India's Central Pollution Control Board (CPCB) issued a clarification circular requiring all pharmaceutical manufacturers holding hazardous-waste authorisation to commission an independent environmental audit by 31 December 2026. This follows a May 2026 pilot audit in Gujarat and Maharashtra that revealed inconsistencies in self-reported waste segregation and disposal records.
The mandate applies to all manufacturing licences (Forms 20 and 20B under the Drugs and Cosmetics Act, 1940) with annual hazardous waste generation above 10 tonnes. Smaller manufacturers (under 10 tonnes annually) face an optional compliance pathway but may face scrutiny under future amendments.
Market signals
CPCB circular dated 15 June 2026 mandates independent environmental audits by accredited auditors (NABET-certified) for all pharma manufacturers with hazardous-waste authorisation. Audit must cover waste segregation, storage, record-keeping, transportation and disposal chain for the preceding 12 months.
State Pollution Control Boards will cross-check audit reports against filed hazardous-waste management plans. Discrepancies flag the facility for unannounced inspection and may delay licence renewal if not rectified within 60 days of audit report submission.
Independent audits typically cost ₹1.5–3 lakhs (₹30,000–60,000 for smaller units) and take 6–8 weeks. Manufacturers must identify and hire auditors by September 2026 to meet the 31 December 2026 deadline, leaving a shrinking window as demand peaks.
Under the Environment (Protection) Act, 1986 and the Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016, this CPCB clarification (issued 15 June 2026) is binding on all State Pollution Control Boards. Pharma manufacturers holding Form 20 or 20B licences must treat the audit as a statutory compliance requirement, not optional. Failure to submit an audit report by 31 December 2026 may result in suspension of the hazardous-waste authorisation and, in turn, suspension of manufacturing licence renewal by state drug authorities. Vinayakam Consultants helps pharma and chemical manufacturers identify accredited auditors, prepare waste-management documentation for audit, and respond to SPCB findings — ensuring the audit process strengthens compliance rather than exposing gaps that invite enforcement action.
Your action checklist
- Verify whether your facility generates ≥10 tonnes of hazardous waste annually (check last 12 months' records); if yes, commission a NABET-accredited environmental auditor by 30 September 2026.
- Collate all hazardous-waste generation, segregation, storage and disposal records (invoices, manifests, certificates from waste management facilities) from the past 12 months and cross-check for gaps or inconsistencies before the audit commences.
- If waste-management practices reveal non-compliance (e.g., incorrect labelling, missing storage records, disposal certificates), rectify immediately and document remedial action to present during the audit.
- Submit the completed audit report to your State Pollution Control Board and maintain a copy on file; flag the 31 December 2026 deadline in your compliance calendar and set a reminder for November 2026 to confirm auditor availability.
Frequently asked questions
The CPCB issued a June 2026 circular requiring all pharma manufacturers with hazardous-waste authorisation to commission independent third-party environmental audits by 31 December 2026, covering waste segregation, storage, and disposal records.
Manufacturers holding Forms 20 and 20B licences under the Drugs and Cosmetics Act with annual hazardous waste generation above 10 tonnes must comply; smaller manufacturers have an optional pathway but face potential future scrutiny.
Independent audits cost ₹1.5–3 lakhs (₹30,000–60,000 for smaller units) and take 6–8 weeks; manufacturers must hire NABET-certified auditors by September 2026 to meet the December 2026 deadline.